INCOG BioPharma Services, a contract development and manufacturing organization (CDMO) specializing in sterile injectable biopharmaceuticals, has announced a significant investment to expand its manufacturing capabilities in Fishers. The expansion includes constructing a second 100,000-square-foot building on its campus, with groundbreaking scheduled for August. This new facility will increase the company’s commercial-scale device assembly capacity, supporting autoinjectors, pens, wearable injectors, and syringe accessorizing, while also adding new labeling and final packaging capabilities.
The addition of this second building will enable INCOG to offer comprehensive, end-to-end solutions from filling to device assembly and final packaging. This streamlined process aims to simplify supply chain solutions for its global biopharma customers.
“We are excited about this new investment and the opportunities it brings,” said Cory Lewis, CEO and Founder of INCOG. “Our customers will have access to a suite of solutions from filling through final packaging. This supply chain integration is essential in accelerating a drug product to commercial launch, and even more important in today’s constrained markets as the need for sterile injectable products is quickly growing to address challenging diseases and improve healthcare outcomes. The hard work and expertise of the team we have built at INCOG has allowed us to accelerate investments and address the immediate needs of the global biopharma industry.”
The expansion is expected to create over 100 additional high-paying jobs in Fishers. The Indiana Economic Development Corporation (IEDC) claims Indiana is the largest exporter of pharmaceutical products in the continental United States. By the end of 2023, Indiana’s Life Science sector included over 3,000 companies, employing 67,000 people and contributing $95 billion to the state’s economy, according to the IEDC.
“We are proud to contribute to the social and economic growth of Fishers by creating new jobs and fostering a vibrant life science community,” added Lewis. “The city and IEDC have served as an extension of our team. It’s exciting to bring current and prospective clients to our facility so they can experience the growing community where we do business.”
Fishers Mayor Scott Fadness expressed his pride in INCOG’s growth and expansion into a second building. “This expansion reinforces Fishers as a leading hub for life sciences and biopharma manufacturing. INCOG has played a significant role in building the industry cluster in Fishers, and we look forward to celebrating their future successes,” Fadness said.
The expansion follows ongoing efforts to commission and install a second high-speed syringe and cartridge filling line, along with supporting automated visual inspection equipment. The new filling line will complement INCOG’s existing multi-use filling line, bringing the site’s filling capacity to 140 million units per year. The automated visual inspection and autoinjector assembly capabilities are already available, with the additional syringe filling capacity expected to come online in Q2 2025. These enhancements will enable INCOG to meet the growing demand for biopharmaceutical solutions that utilize pre-filled syringes and autoinjector delivery mechanisms.